Due to their rarity and high level of symptom complexity, rare diseases are often hard to diagnose, and there is still no cure for most rare diseases and few treatments. Since 72% of rare diseases are caused by genetic disorders, gene therapy is a promising treatment option that brings hope to rare disease patients. However, significant preclinical research is needed to lay the foundation for any treatment before applying it to human beings. Genetically engineered mouse or rat models that can display some (or all) the pathological processes in an actual human patient with these diseases play an important role in rare disease research.
To understand disease mechanisms and explore effective therapeutic targets, the selection of experimental models is essential. In this on-demand Webinar, Dr. Marvin Ouyang, Executive Vice President and Chief Scientific Officer of Cyagen, explains the current research progress on rare diseases, introduces successful cases of using animal models in rare disease therapeutic research and effective gene-editing strategies that can accelerate your research progress!
Cyagen is a 700-employee company headquartered in Santa Clara, California, with additional locations in Japan and production facilities in China. Cyagen is a leading provider of complete research model solutions. We offer a “one-stop-shop” tailored to biomedical scientists’ gene research needs.
Our comprehensive services cover the entire process of animal model generation: from transgenic/gene targeting strategy design to animal model development, breeding, cryopreservation, and animal phenotype analysis. In addition, our virus products and services are widely used in the construction of various cell models, in vivo injection of living animals, gene therapy, and other research fields.
>> For more information about gene editing strategy and model selection, Contact us with your project information, and our experts will be in touch within 48 hours.
We will respond to you in 1-2 business days.